Drug Profile
Research programme: exosome-based therapeutics - Celltex Therapeutics/Texas A & M Institute
Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Texas A&M University
- Developer Celltex Therapeutics; Texas A&M University
- Class Anti-inflammatories; Antidementias; Exosome therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for research development in Alzheimer's-disease in USA
- 16 Mar 2020 Celltex Therapeutics enters into and holds exclusive license agreement with Texas A&M institute related to several A-1 Exosome Patent Applications covering composition of matter and methods claims in US, Europe, Mexico and Saudi Arabia
- 12 Feb 2018 Celltex Therapeutics in-licenses mesenchymal stem cell-derived exosomes from Texas A&M University